Member Info for Timster

Saying that though the DRVG CEO used to post on their board....

Big AL, is that you? Does it work?

It works

I think it will be us too...

I was expecting the crew to jump on the fact that this trial is ahead of us and we are doomed.
Ignoring the fact that thousands of cancer trials are in progress ..

As you were...

Is it us???

Could be the avct inflection point we are waiting for... Avct SP loves an odx RNS...

WHy AR THERE POsTS!!!! WHY!!!! WHY!!!!!!!!

Just like he'd never go into the last AGM without the data catiousoptimist? :)

Great post, very comfortable with the investment in Avacta.
Clearly fantastic progress is being made across multiple fronts.

Last wress related post from me, as we can see a serial twat.

Wress's arrival on the Avacta board:

Wressmycash Premium Member

Posted in: AVCT

Posts: 1,713

Price: 114.40

No Opinion

£10 09 May 2022 17:09
A share on good news of trial
Every man and his dog will be scrambling to get in

followed by reams and reams of ramping, posting old news articles and trades he claims to have made.
Then the flip to deramping:

Wressmycash Premium Member

Posted in: AVCT

Posts: 1,713

Price: 97.50

No Opinion

Failure is not an option?19 Jun 2022 08:02
It takes 10 to 15 years and around US$1 billion to develop one successful drug. Despite these significant investments in time and money, 90% of drug candidates in clinical trials fail.23 Feb 2022
https://theconversation.com/amp/90-of-drugs-fail-clinical-trials-heres-one-way-researchers-can-select-better-drug-candidates-174152

Twat

In a week with two very promising news items it's been crap on the SP front.
But there have been some great threads on here this week, keep it up people, great discussions being had.

Most interest for future tests based on this platform would be professional settings I guess, although they do say they will target consumer settings.

Focused on developing a broad IVD product portfolio to serve the professional use and consumer home test market.

https://www.bbc.co.uk/news/live/uk-62008118
I know we don't care but if we do ever get this back on the market there might be a small market opportunity.
But I would agree in a saturated market with extremely cheap Chinese pap its not that material.

The wider goal is perfecting a platform and process for the dx division to be able to generate affimers and tests quickly and at scale for a large range of targets.

Yep pre|CISION™ is the platform
It opens up a while pipeline of prodrugs if this trial is successful, they've already started work on this lot
preCISION Velcade ($1.2bn sales) (AVA3996)
preCISION Paclitaxel ($2.96bn sales) preCISION Oxaliplatin
preCISION Gemcitabine
preCISION Capecitabine
preCISION PARP inhibitor
preCISION PD1 Inhibitor
preCISION AKT inhibitor
preCISION Balixafortide

https://avacta.com/wp-content/uploads/2022/02/Feb-2022-investor-presentation.pdf

Slide 12

In another place in the slides it says late Q3/early Q4 so they are looking end of September minimum

Fascinating.... Tell us more.... Zzzzzzzzzzzzzzzzzzzz

Wouldn't have thought we'd be down today but hey ho

AgentB knows!!

Seems to be all about trial data, fair enough I guess but there must be some value in these announcements Shirley.

End of Q3 it is then, inflection ahoy...